Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells

Hepatocellular carcinoma (HCC) is one of the common malignancies and is an increasingly important cause of cancer death worldwide. Surgery, chemotherapy, and radiation therapy extend the 5-year survival limit in HCC patients by only 6%. Therefore, there is a need to develop new therapeutic approache...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cell Death Dis
Autores principales: Augello, Giuseppa, Modica, Martina, Azzolina, Antonina, Puleio, Roberto, Cassata, Giovanni, Emma, Maria Rita, Di Sano, Caterina, Cusimano, Antonella, Montalto, Giuseppe, Cervello, Melchiorre
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833482/
https://ncbi.nlm.nih.gov/pubmed/29348495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-017-0195-0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares